Earnings Call · Q2 FY2023·2023-08-02

Q2 23EPS -10.00%·Rev n/aQ1 23EPS -6.25%·Rev n/aQ4 22EPS +6.67%·Rev n/aQ3 22EPS 0.00%·Rev n/a⚠ consensus missing

Evolus, Inc. EOLS

David Erickson — Investor Relations or similar role

David Moatazedi — President and Chief Executive Officer

Rui Avelar — Chief Medical Officer, Head of R&D

Sandra Beaver — Chief Financial Officer

+2.1%1d on move date+2.4% vs SPY3d−5.2%5d−5.8%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more EOLS calls or request research access.

More EOLS calls Browse calls Request research access